EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing

Elisabet Zapatero-Solana, Yan Ding, Nicholas Pulliam, Alfonso de Dios, Maria Jesus Ortiz-Ruiz, María José Lallena

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26062643 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Elisabet Zapatero-Solana und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lilly S.A.U., Cell Biology & Translational, DCRT, 28108 Madrid, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CDK4/6 inhibitors (CDK4/6i) combined with hormone therapies have demonstrated clinical benefit in HR+, HER2- breast cancer patients. However, the onset of resistance remains a concern and highlights a need for therapeutic strategies to improve outcomes. The objective of this study was to develop an in vitro model to better understand the mechanisms of resistance to CDK4/6i + hormone therapies and identify therapeutic strategies with potential to overcome this resistance.

Methods

The HR+, HER2− T47D breast cancer cell line genetically modified with a Geminin–Venus reporter construct was treated with CDK4/6i (abemaciclib or palbociclib) in combination with 4-hydroxytamoxifen (tamoxifen). Resistant cells were identified by cell sorting for Geminin (%GEM+), a marker of the S/G2/M phases of the cell cycle, and confirmed by treatment with tamoxifen plus the CDK4/6i used to drive resistance. In resistant cells, following treatment with CDK4/6i + ET (tamoxifen or fulvestrant), the effects on cell proliferation (%GEM+) and viability, gene expression, and protein analysis to evaluate CDK4/6–cyclin D complex composition were examined.

Results

Palbociclib + tamoxifen-resistant (PTxR) cells treated with abemaciclib + ET showed decreased %GEM+, %Ki67, and colony formation ability, compared to abemaciclib + tamoxifen-resistant (ATxR) cells treated with palbociclib + ET. Additionally, PTxR cells showed increased CDK4-p21 interaction, compared to ATxR. The CDK6 levels were greater in ATxR cells compared to PTxR cells, associated with CDK4/6i resistance. Additionally, abemaciclib + fulvestrant continued to robustly decrease pRb levels in PTxR models compared to palbociclib + fulvestrant in ATxR models. Transcriptome analysis revealed a depression of the cell cycle and E2F- and Rb-related genes in PTxR cells following treatment with abemaciclib + ET, not present in ATxR cells treated with palbociclib + ET. Both resistant models showed increased EGFR-related gene expression.

Conclusion

Taken together, we describe CDK4/6i-dependent mechanisms resulting in early-onset resistance to CDK4/6i + ET, using clinically relevant drug concentrations, in preclinical breast cancer cell models. The characterization of these preclinical models post progression on CDK4/6 inhibitor + ET treatment highlights the potential that the specific sequencing of CDK4/6 inhibitors could offer to overcome acquired resistance to CDK4/6i + ET. Abemaciclib + fulvestrant is currently under clinical investigation in patients with HR+, HER2− breast cancer and progression on prior CDK4/6i + ET (NCT05169567, postMONARCH).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Drug Resistance, NeoplasmProtein Kinase InhibitorsFemaleHumansAcrylamidesAminopyridinesBenzimidazolesCell Line, TumorCell ProliferationFulvestrantGene Expression Regulation, NeoplasticPiperazinesPyridinesTamoxifen

Stichwörter der Autor:innen

CDK4/6 inhibitorabemaciclibbreast cancerendocrine therapyresistance

Substanzen

abemaciclibAcrylamidesafimoxifeneAminopyridinesBenzimidazolesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Fulvestrant

Autor:innen und Institutionen

  • Lilly S.A.U., Cell Biology & Translational, DCRT, 28108 Madrid, Spain.
  • Eli Lilly and Company, Indianapolis, IN 46285, USA.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Zapatero-Solana, E., Ding, Y., Pulliam, N., de Dios, A., Ortiz-Ruiz, M. J., & Lallena, M. J. (2025). Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062643

Vancouver

Zapatero-Solana E, Ding Y, Pulliam N, de Dios A, Ortiz-Ruiz MJ, Lallena MJ. Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062643

BibTeX
@article{ZapateroSolana2025,
  author = {Zapatero-Solana, Elisabet and Ding, Yan and Pulliam, Nicholas and de Dios, Alfonso and Ortiz-Ruiz, Maria Jesus and Lallena, María José},
  title = {Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26062643}
}
Kostenlos starten →